Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma

被引：0
|
作者：
Baz, Rachid [1 ]
Alsina, Melissa
Shain, Kenneth H. [1 ]
Paleveda, Jennifer [1 ]
Hillgruber, Nancy [1 ]
Finley-Oliver, Elizabeth [1 ]
Ochoa, Leonel
Nishihori, Taiga
Dalton, William [2 ]
Sullivan, Daniel
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Personalized Med Inst, Tampa, FL 33612 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4060.4060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4060
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma
    Fiala, Mark A.
    Wildes, Tanya M.
    Shah, Gunjan L.
    Ghobadi, Armin
    Schroeder, Mark A.
    Stockerl-Goldstein, Keith E.
    Vij, Ravi
    BLOOD, 2017, 130
  • [32] Lenalidomide and Dexamethasone Therapy in Elderly Patients with Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide
    Kobayashi, Takahiro
    Miura, Masatomo
    Niioka, Takenori
    Fujioka, Yuki
    Abumiya, Maiko
    Yoshioka, Tomoko
    Kameoka, Yoshihiro
    Nishikawa, Hiroyoshi
    Takahashi, Naoto
    BLOOD, 2017, 130
  • [33] Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement
    Dispenzieri, Angela
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Fonseca, Rafael
    Lacy, Martha Q.
    Bergsagel, P. Leif
    Kyle, Robert A.
    Greipp, Philip R.
    Witzig, Thomas E.
    Reeder, Craig B.
    Lust, John A.
    Russell, Stephen J.
    Hayman, Suzmnwe R.
    Roy, Vivek
    Kumar, Shaji
    Zeldenrust, Steven R.
    Dalton, Robert J.
    Stewart, A. Keith
    MAYO CLINIC PROCEEDINGS, 2007, 82 (03) : 323 - 341
  • [34] Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan
    Suzuki, Tomotaka
    Maruyama, Dai
    Iida, Shinsuke
    Nagai, Hirokazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (09) : 966 - 974
  • [35] Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma
    Bici, Anisa
    Pianko, Matthew J.
    Nachar, Victoria R.
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 407 - 414
  • [36] Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status
    Landgren, Ola
    SEMINARS IN ONCOLOGY, 2016, 43 (06) : 703 - 706
  • [37] Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients
    Korde, Neha
    Dosani, Talib
    Simakova, Olga
    Mailankody, Sham
    Costello, Rene
    Roschewski, Mark
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Figg, William D.
    Landgren, Ola
    Maric, Irina
    BLOOD, 2014, 124 (21)
  • [38] Sustained response to single agent therapy with continuous lenalidomide in a pre-treated high-risk multiple myeloma patient
    E. Willenbacher
    W. Willenbacher
    E. Gunsilius
    memo - Magazine of European Medical Oncology, 2012, 5 (1) : 27 - 29
  • [39] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
    Tan, Carlyn
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Patel, Dhwani
    Maclachlan, Kylee H.
    Lahoud, Oscar B.
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Korde, Neha
    Usmani, Saad
    BLOOD, 2022, 140 : 1817 - 1819
  • [40] Sustained response to single agent therapy with continuous lenalidomide in a pre-treated high-risk multiple myeloma patient
    Willenbacher, E.
    Willenbacher, W.
    Gunsilius, E.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2012, 5 (01) : 27 - 29
12345